๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Beijing 25 Wuhan 15 Hangzhou 13 Nanjing 12
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai53 Beijing25 Wuhan15 Hangzhou13 Nanjing12
All 38 locations
Target enrolment
to

Trials with a site in Nanjing

12 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
NCT07589569Pancreatic Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 2
92
Nanjing, Tianjin
2026-06-04
Recruiting
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
NCT07353645Colorectal Cancer, Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
49
Nanjing
2026-03-23
Not yet open
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
NCT06177522Pancreatic Cancer, Neoadjuvant Therapy
Jinling Hospital, China
Phase 2
30
Nanjing
2025-11-30
Not yet open
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
NCT06779318Pancreatic Cancer, Postoperative Adjuvant Therapy, Maintenance Therapy
The First Affiliated Hospital with Nanjing Medical University
Phase 4
464
Nanjing
2025-07
Recruiting
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
NCT06937112Lung Cancers, Pancreatic Cancer, Neuroendocrine Tumors, Thyroid Cancer
Nanjing First Hospital, Nanjing Medical University
Observational
20
Nanjing
2025-04-10
Recruiting
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
NCT07054879Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
70
Nanjing
2024-11-01
Active, closed
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
NCT06766019Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
47
Nanjing
2024-10-16
Recruiting
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
NCT06361316Pancreatic Cancer, Adjuvant Therapy
Kuirong Jiang
Not applicable
53
Nanjing
2024-04-08
Recruiting
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
NCT06326736Pancreatic Cancer
Jinling Hospital, China
Phase EARLY_PHASE1
12
Nanjing
2024-04
Recruiting
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
NCT06151262Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
30
Nanjing
2024-01-20
Recruiting
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
NCT06389760Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
57
Nanjing
2023-10-18
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies with a site in Nanjing that also match the filters currently applied.

How many clinical trials are recruiting in Nanjing?

8 of the 12 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanjing), 12 studies
PhaseStudiesRecruitingShare
Phase 25341.7%
Observational2216.7%
Phase 1/22116.7%
Not applicable118.3%
Phase 4108.3%
Phase EARLY_PHASE1118.3%

Most active sponsors

Lead sponsors with the most studies (Nanjing)
Lead sponsorStudiesRecruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School44
Jinling Hospital, China21
The First Affiliated Hospital with Nanjing Medical University20
CARsgen Therapeutics Co., Ltd.10
Kuirong Jiang11
Nanjing First Hospital, Nanjing Medical University11
Shandong Suncadia Medicine Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.